Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2 - 22/07/20
![](/templates/common/images/mail.png)
This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Department of Health and Human Services, under grant numbers 1UM1AI114271-01, UM2AI117870, 5UM1AI114271-03, and UM1AI109565. Additional support was provided by the National Heart, Lung, and Blood Institute, NIH, through grant number RO1HL12384, and National Center for Advancing Translational Sciences, NIH, through grant numbers UL1TR001079, 1UL1TR001430, UL1TR001873, and UL1TR002345. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. The co-authorship by Drs Gergen, Becker, and Togias on this publication does not necessarily constitute endorsement by the National Institute of Allergy and Infectious Diseases, the NIH or any other agency of the United States government. |
|
Disclosure of potential conflict of interest: D. J. Jackson reports grants from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID)/National Heart, Lung and Blood Institute (NHLBI) and GlaxoSmithKline, as well as personal fees from Pfizer for data and safety and monitoring board participation and personal consulting fees from Novartis, Sanofi-Regeneron, GlaxoSmithKline, Vifor Pharma, and AstraZeneca. W. W. Busse reports grants from the NIH/NIAID/NHLBI during the conduct of the study, as well as personal fees from Novartis, Sandoz, Regeneron, AstraZeneca, GlaxoSmithKline, Genentech, Teva, Elsevier, Arrowhead, resTORbio, Med Learning Group, Practicing Clinicians Exchange, Boston Scientific, and Medscape. L. B. Bacharier reports grant support from the NIH/NIAID/NHLBI, Sanofi, and Vectura, as well as personal fees from GlaxoSmithKline, Genentech, Novartis, Merck, DBV Technologies, Teva, Boehringer Ingelheim, AstraZeneca, WebMD/Medscape, Sanofi, Regeneron, Vectura, and Circassia. R. A. Wood receives grant support from the NIH, Astellas, Aimmune, DBV, Sanofi, and Regeneron, as well as royalties from Up To Date. J. E. Gern reports grants from the NIH; personal fees and stock options from Meissa Vaccines, Inc; personal fees from AstraZeneca and Ena Therapeutics; and a patent on methods for production of rhinoviruses. Dr. Altman reports personal fees from Regeneron for consulting. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 146 - N° 1
P. 203 - Luglio 2020 Ritorno al numeroBenvenuto su EM|consulte, il riferimento dei professionisti della salute.